• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

D936Y 和 SARS-CoV-2 刺突蛋白七肽重复 1 融合核心中的其他突变:频率、地理分布和结构效应。

D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect.

机构信息

Department of Sciences and Technologies, University Parthenope of Naples, Centro Direzionale Isola C4, I-80143 Naples, Italy.

Kaust Catalysis Center, Physical Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.

出版信息

Molecules. 2021 Apr 30;26(9):2622. doi: 10.3390/molecules26092622.

DOI:10.3390/molecules26092622
PMID:33946306
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8124767/
Abstract

The crown of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is constituted by its spike (S) glycoprotein. S protein mediates the SARS-CoV-2 entry into the host cells. The "fusion core" of the heptad repeat 1 (HR1) on S plays a crucial role in the virus infectivity, as it is part of a key membrane fusion architecture. While SARS-CoV-2 was becoming a global threat, scientists have been accumulating data on the virus at an impressive pace, both in terms of genomic sequences and of three-dimensional structures. On 15 February 2021, from the SARS-CoV-2 genomic sequences in the GISAID resource, we collected 415,673 complete S protein sequences and identified all the mutations occurring in the HR1 fusion core. This is a 21-residue segment, which, in the post-fusion conformation of the protein, gives many strong interactions with the heptad repeat 2, bringing viral and cellular membranes in proximity for fusion. We investigated the frequency and structural effect of novel mutations accumulated over time in such a crucial region for the virus infectivity. Three mutations were quite frequent, occurring in over 0.1% of the total sequences. These were S929T, D936Y, and S949F, all in the N-terminal half of the HR1 fusion core segment and particularly spread in Europe and USA. The most frequent of them, D936Y, was present in 17% of sequences from Finland and 12% of sequences from Sweden. In the post-fusion conformation of the unmutated S protein, D936 is involved in an inter-monomer salt bridge with R1185. We investigated the effect of the D936Y mutation on the pre-fusion and post-fusion state of the protein by using molecular dynamics, showing how it especially affects the latter one.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的冠状结构由其刺突(S)糖蛋白构成。S 蛋白介导 SARS-CoV-2 进入宿主细胞。S 上的七肽重复 1(HR1)的“融合核心”在病毒感染力中起着至关重要的作用,因为它是关键膜融合结构的一部分。当 SARS-CoV-2 成为全球威胁时,科学家们以惊人的速度积累了有关该病毒的大量数据,无论是在基因组序列方面还是在三维结构方面。2021 年 2 月 15 日,我们从 GISAID 资源中的 SARS-CoV-2 基因组序列中收集了 415,673 个完整的 S 蛋白序列,并确定了 HR1 融合核心中发生的所有突变。这是一个 21 个残基的片段,在蛋白的融合后构象中,与七肽重复 2 形成许多强相互作用,使病毒和细胞膜接近融合。我们研究了在如此重要的病毒感染性区域中随时间积累的新型突变的频率和结构效应。有三个突变非常频繁,发生在超过总序列的 0.1%。这些突变是 S929T、D936Y 和 S949F,均位于 HR1 融合核心片段的 N 端,特别在欧洲和美国传播。其中最常见的突变,D936Y,出现在芬兰序列的 17%和瑞典序列的 12%中。在未突变的 S 蛋白的融合后构象中,D936 与 R1185 形成单体间盐桥。我们通过使用分子动力学研究了 D936Y 突变对蛋白的预融合和融合后状态的影响,结果表明它特别影响后者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/c52e90cf127f/molecules-26-02622-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/2a14a180db61/molecules-26-02622-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/545ac8d34bed/molecules-26-02622-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/7e01dd29e779/molecules-26-02622-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/144c4540e90e/molecules-26-02622-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/c52e90cf127f/molecules-26-02622-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/2a14a180db61/molecules-26-02622-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/545ac8d34bed/molecules-26-02622-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/7e01dd29e779/molecules-26-02622-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/144c4540e90e/molecules-26-02622-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35e6/8124767/c52e90cf127f/molecules-26-02622-g005.jpg

相似文献

1
D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect.D936Y 和 SARS-CoV-2 刺突蛋白七肽重复 1 融合核心中的其他突变:频率、地理分布和结构效应。
Molecules. 2021 Apr 30;26(9):2622. doi: 10.3390/molecules26092622.
2
Spike protein fusion loop controls SARS-CoV-2 fusogenicity and infectivity.刺突蛋白融合环控制 SARS-CoV-2 的融合性和感染性。
J Struct Biol. 2021 Jun;213(2):107713. doi: 10.1016/j.jsb.2021.107713. Epub 2021 Mar 1.
3
The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2.D614G 突变对 SARS-CoV-2 刺突糖蛋白结构的影响。
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9). doi: 10.1073/pnas.2022586118.
4
Stabilizing the closed SARS-CoV-2 spike trimer.稳定闭合的 SARS-CoV-2 刺突三聚体。
Nat Commun. 2021 Jan 11;12(1):244. doi: 10.1038/s41467-020-20321-x.
5
Insights into the structural and dynamical changes of spike glycoprotein mutations associated with SARS-CoV-2 host receptor binding.解析与 SARS-CoV-2 宿主受体结合相关的刺突糖蛋白突变的结构和动力学变化。
J Biomol Struct Dyn. 2022 Jan;40(1):263-275. doi: 10.1080/07391102.2020.1811774. Epub 2020 Aug 27.
6
Structural basis of severe acute respiratory syndrome coronavirus 2 infection.严重急性呼吸综合征冠状病毒 2 感染的结构基础。
Curr Opin HIV AIDS. 2021 Jan;16(1):74-81. doi: 10.1097/COH.0000000000000658.
7
Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation.ACE2 表达中的遗传变异性对 SARS-CoV-2 刺突 D614G 突变进化动态的影响。
Genes (Basel). 2020 Dec 24;12(1):16. doi: 10.3390/genes12010016.
8
Questions concerning the proximal origin of SARS-CoV-2.关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)近端起源的问题。
J Med Virol. 2021 Mar;93(3):1204-1206. doi: 10.1002/jmv.26478. Epub 2020 Dec 30.
9
In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.基于 SARS-CoV-2 刺突糖蛋白与 ACE-2 受体同源物和人类 TLR 相互作用的比较特征的计算机研究。
J Med Virol. 2020 Oct;92(10):2105-2113. doi: 10.1002/jmv.25987. Epub 2020 May 17.
10
Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis.刺突蛋白与 SARS-CoV-2 脂膜与熊去氧胆酸的相互作用:一项计算机模拟分析。
Sci Rep. 2021 Nov 15;11(1):22288. doi: 10.1038/s41598-021-01705-5.

引用本文的文献

1
COVID-19 Variants and Vaccine Development.新型冠状病毒变异株与疫苗研发。
Viruses. 2024 May 10;16(5):757. doi: 10.3390/v16050757.
2
Ensemble-Based Mutational Profiling and Network Analysis of the SARS-CoV-2 Spike Omicron XBB Lineages for Interactions with the ACE2 Receptor and Antibodies: Cooperation of Binding Hotspots in Mediating Epistatic Couplings Underlies Binding Mechanism and Immune Escape.基于集成的SARS-CoV-2刺突奥密克戎XBB谱系与ACE2受体及抗体相互作用的突变分析和网络分析:结合热点在介导上位性偶联中的协同作用是结合机制和免疫逃逸的基础
Int J Mol Sci. 2024 Apr 12;25(8):4281. doi: 10.3390/ijms25084281.
3
High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1.

本文引用的文献

1
Characterization of Structural and Energetic Differences between Conformations of the SARS-CoV-2 Spike Protein.严重急性呼吸综合征冠状病毒2刺突蛋白不同构象之间的结构和能量差异的表征
Materials (Basel). 2020 Nov 26;13(23):5362. doi: 10.3390/ma13235362.
2
Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020.2020 年 1 月至 6 月,世卫组织欧洲区域内 SARS-CoV-2 谱系的地理和时间分布。
Euro Surveill. 2020 Aug;25(32). doi: 10.2807/1560-7917.ES.2020.25.32.2001410.
3
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.
高融合率和 SARS-CoV-2 变体 B.1.640.1 的细胞病变效应。
J Virol. 2024 Jan 23;98(1):e0135123. doi: 10.1128/jvi.01351-23. Epub 2023 Dec 13.
4
Structural and pKa Estimation of the Amphipathic HR1 in SARS-CoV-2: Insights from Constant pH MD, Linear vs. Nonlinear Normal Mode Analysis.SARS-CoV-2 中两亲性 HR1 的结构和 pKa 估算:恒 pHMD、线性与非线性正则模态分析的启示。
Int J Mol Sci. 2023 Nov 10;24(22):16190. doi: 10.3390/ijms242216190.
5
Distribution and Functional Analyses of Mutations in Spike Protein and Phylogenic Diversity of SARS-CoV-2 Variants Emerged during the Year 2021 in India.2021年印度出现的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株刺突蛋白突变的分布与功能分析及系统发育多样性
J Glob Infect Dis. 2023 May 17;15(2):43-51. doi: 10.4103/jgid.jgid_178_22. eCollection 2023 Apr-Jun.
6
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.抗靶标,抗 SARS-CoV-2 先导物,药物,以及药物发现遗传学联盟的视角。
J Med Chem. 2023 Mar 23;66(6):3664-3702. doi: 10.1021/acs.jmedchem.2c01229. Epub 2023 Mar 1.
7
Immunoinformatics-Aided Design of a Peptide Based Multiepitope Vaccine Targeting Glycoproteins and Membrane Proteins against Monkeypox Virus.基于免疫信息学的猴痘病毒糖蛋白和膜蛋白多表位肽疫苗设计。
Viruses. 2022 Oct 27;14(11):2374. doi: 10.3390/v14112374.
8
Immunoinformatics Aided Design and Validation of a Cross-Reactive Peptide Based Multi-Epitope Vaccine Targeting Multiple Serotypes of Dengue Virus.基于免疫信息学设计和验证的针对多种血清型登革热病毒的交叉反应性肽多表位疫苗。
Front Immunol. 2022 Jun 21;13:865180. doi: 10.3389/fimmu.2022.865180. eCollection 2022.
9
In Silico Screening and Testing of FDA-Approved Small Molecules to Block SARS-CoV-2 Entry to the Host Cell by Inhibiting Spike Protein Cleavage.通过抑制刺突蛋白裂解阻断 SARS-CoV-2 进入宿主细胞的 FDA 批准的小分子的计算机筛选和测试。
Viruses. 2022 May 24;14(6):1129. doi: 10.3390/v14061129.
10
The phylodynamics of SARS-CoV-2 during 2020 in Finland.2020年芬兰境内严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的系统动力学
Commun Med (Lond). 2022 Jun 10;2:65. doi: 10.1038/s43856-022-00130-7. eCollection 2022.
SARS-CoV-2 刺突突变对病毒感染力和抗原性的影响。
Cell. 2020 Sep 3;182(5):1284-1294.e9. doi: 10.1016/j.cell.2020.07.012. Epub 2020 Jul 17.
4
SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.SARS-CoV-2 刺突蛋白:疫苗的最佳免疫靶标。
J Transl Med. 2020 Jun 3;18(1):222. doi: 10.1186/s12967-020-02392-y.
5
Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.SARS-CoV-2 刺突蛋白中与 ACE2 和中和抗体相互作用的受体结合基序的关键残基。
Cell Mol Immunol. 2020 Jun;17(6):621-630. doi: 10.1038/s41423-020-0458-z. Epub 2020 May 15.
6
Cell entry mechanisms of SARS-CoV-2.SARS-CoV-2 的细胞进入机制。
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734. doi: 10.1073/pnas.2003138117. Epub 2020 May 6.
7
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.针对高融合活性新兴冠状病毒 SARS-CoV-2 的有效膜融合抑制剂设计。
J Virol. 2020 Jul 1;94(14). doi: 10.1128/JVI.00635-20.
8
A human monoclonal antibody blocking SARS-CoV-2 infection.一种人源单克隆抗体阻断 SARS-CoV-2 感染。
Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
9
Candidate drugs against SARS-CoV-2 and COVID-19.针对 SARS-CoV-2 和 COVID-19 的候选药物。
Pharmacol Res. 2020 Jul;157:104859. doi: 10.1016/j.phrs.2020.104859. Epub 2020 Apr 29.
10
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.利用人血管紧张素转化酶 2 进入 SARS-CoV-2 的结构和功能基础
Cell. 2020 May 14;181(4):894-904.e9. doi: 10.1016/j.cell.2020.03.045. Epub 2020 Apr 9.